CVS expects FY adjusted EPS of $7.90 to $8.10, versus the IBES estimate of $7.45.
CVS expects FY cash flow from operations of at least $11.5 billion.
The company said it is maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.
Pricing and virtual visit plans
CVS said that by early Q4, Zepbound and Foundayo patients will be able to view transparent pricing, including cash-pay options.
CVS also said it will offer $29 MinuteClinic virtual visits for patients seeking GLP-1 medications.
Second-quarter results beat estimates
CVS Q2 adjusted EPS was $2.58, versus the IBES estimate of $1.85.
CVS Q2 revenue was $106.10 billion, versus the IBES estimate of $100.11 billion.
CVS Q2 medical benefit ratio was , versus the IBES estimate of .
CVS•
